SCHEMBL3564439

SCHEMBL3564439

COc1ccccc1-c1c[nH]c2ncc(-c3cc(Cl)c(O)c(C(=O)O)c3)cc12

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.60
ABL1 P00519 1/20 0.58
CAMKK2 Q96RR4 6/20 0.50
AAK1 Q2M2I8 2/20 0.50
KIT P10721 2/20 0.50
MAP3K11 Q16584 1/20 0.49
SGK1 O00141 2/20 0.48
AXL P30530 4/20 0.48
NEK1 Q96PY6 1/20 0.48
RIPK1 Q13546 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13342256 0.90 MAP4K1 (0.72) MAP4K1ABL1CAMKK2AAK1KIT
SCHEMBL13342249 0.85 KIT (0.58) MAP4K1ABL1CAMKK2KITMAP3K11
SCHEMBL3488761 0.84 AKR1C2 (0.45) MAP4K1ABL1AAK1AXL
SCHEMBL12762899 0.82 MAP4K1 (0.60) MAP4K1ABL1AAK1KIT
SCHEMBL13342206 0.82 MAP4K1 (0.76) MAP4K1ABL1CAMKK2AAK1KIT
SCHEMBL14413466 0.82 MAP4K1 (0.53) MAP4K1ABL1CAMKK2AAK1KIT
SCHEMBL13342241 0.81 MAP4K1 (0.52) MAP4K1ABL1CAMKK2KITMAP3K11
SCHEMBL13342276 0.81 MAP4K1 (0.52) MAP4K1ABL1CAMKK2KITMAP3K11
SCHEMBL13342280 0.81 MAP4K1 (0.52) MAP4K1ABL1CAMKK2KITMAP3K11
SCHEMBL3568852 0.80 MAP4K1 (0.51) MAP4K1ABL1CAMKK2KITMAP3K11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
US-7709645-B2 Pyrrolo-pyridine kinase modulators SGX PHARMACEUTICALS, INC. (US) 2010-05-04 US disclosed
EP-2134343-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-12-23 EP disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS SGX PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed
WO-2008124849-A2 PYRROLO-PYRIDINE KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143352-A1 PYRROLO-PYRIDINE KINASE MODULATIORS MAP4K2, PDXK, MAP4K1 MAP4K1 3/4885ABL1 348/4885CAMKK2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.